Skip to content

SYROS PHARMACEUTICALS, INC.

CIK 0001556263

← back to feed
Revenue (TTM)
$13.44M
−33.2% YoY Q3 Oct 2024
Net Income (TTM)
−$73.57M
−73.9% YoY Q3 Oct 2024
EPS Diluted (TTM)
−$2.28
+22.4% YoY Q3 Oct 2024
Gross Margin
—
Q3 Oct 2024
Operating Margin
-886.6%
Q3 Oct 2024
Net Margin
-547.4%
Q3 Oct 2024
Free Cash Flow (TTM)
−$122.43M
Q3 Oct 2024
Cash
$58.28M
Q3 Oct 2024
Total Debt
$52.75M
Q3 Oct 2024
Shares Outstanding
26.83M sh
Q3 Oct 2024

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings